Price alert —
Sign in to get a one-time email the moment CRSP crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · CRSP
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -12293.1% | -13024.8% |
| 2025-12-31 | — | $-0.1B | $-0.2B | $-0.1B | — | — |
| 2025-09-30 | — | $-0.1B | $-0.1B | $-0.1B | — | — |
| 2025-06-30 | — | $-0.2B | $-0.2B | $-0.1B | — | — |
| 2025-03-31 | — | $-0.1B | $-0.1B | $-0.1B | — | — |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare CRSP vs peers
Line CRSP up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with CRSP
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-04 | -1.28 | -1.23 | -3.7% | -2.2% |
| 2026-02-12 | -1.37 | -1.23 | -11.7% | +8.5% |
| 2025-11-10 | -1.17 | -1.29 | +9.2% | +1.1% |
| 2025-08-04 | -1.29 | -1.40 | +7.8% | -6.7% |
| 2025-05-06 | -1.58 | -1.28 | -23.8% | +3.3% |
| 2025-02-11 | -0.44 | -1.19 | +62.9% | +9.3% |
| 2024-11-05 | -1.01 | -1.40 | +28.1% | +0.7% |
| 2024-08-05 | -1.49 | -1.43 | -4.4% | -0.7% |
| 2024-05-08 | -1.43 | -1.46 | +2.4% | +0.5% |
| 2024-02-21 | 1.10 | 0.05 | +2212.9% | +4.6% |
| 2023-11-06 | -1.41 | -1.95 | +27.7% | +13.6% |
| 2023-08-07 | -0.98 | -2.10 | +53.4% | +9.7% |
| 2023-05-08 | -0.67 | -1.64 | +59.1% | +13.3% |
| 2023-02-21 | -1.41 | -2.27 | +37.9% | +8.0% |
| 2022-11-01 | -2.24 | -2.24 | -0.1% | +5.1% |
| 2022-08-08 | -2.40 | -2.21 | -8.8% | -7.7% |
| 2022-05-09 | -2.32 | -1.97 | -17.6% | +9.4% |
| 2022-02-15 | -1.84 | -1.78 | -3.4% | +1.6% |
| 2021-11-03 | -1.67 | -1.76 | +5.3% | -4.0% |
| 2021-07-29 | 9.44 | 3.12 | +202.6% | +1.7% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| CRSP ★ | $5B | — | -12.1 | 1131.4 | -5.6 | 2.5 | — | 68.6% | — | -5.62% |
| LLY | $1,040B | 41.5 | 26.0 | — | 30.0 | 33.4 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $393B | 32.6 | 19.3 | 0.9 | 18.1 | 3.8 | 19.5% | 0.4% | 61.5% | 5.79% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $316B | 36.0 | 13.3 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.45% |
| ABBV | $452B | 124.7 | 15.7 | 7.2 | 17.2 | -67.9 | 72.0% | 12.4% | -46.2% | 4.61% |
| PFE | $142B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.69% |
| TMO | $194B | 28.7 | 19.2 | — | 20.8 | 3.7 | 40.9% | 6.2% | 11.3% | 2.85% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 48.05%
| Holder | Shares | % out |
|---|---|---|
| ARK Investment Management, LLC | 11,313,623 | 11.73% |
| Blackrock Inc. | 7,680,073 | 7.96% |
| Orbis Allan Gray Ltd | 6,106,011 | 6.33% |
| Capital World Investors | 4,725,037 | 4.90% |
| State Street Corporation | 3,982,500 | 4.13% |
| GSK plc | 3,220,627 | 3.34% |
| T. Rowe Price Investment Management, | 2,952,595 | 3.06% |
| Geode Capital Management, LLC | 2,377,164 | 2.46% |
| SR One Capital Management, LP | 2,038,763 | 2.11% |
| FMR, LLC | 1,954,694 | 2.03% |
Insider activity · 90d
13 buys / 1 sells · ratio 13.0 · Finnhub
- Fleming Harold Edward BUY 13,000
- Rommel Christian BUY 13,000
- Treco Douglas A BUY 13,000
- Morrison Briggs BUY 13,000
- High Katherine A BUY 13,000
- Behbahani Ali BUY 13,000
- Greene John BUY 13,000
- George Simeon BUY 13,000
- Fardis Maria BUY 13,000
- Mahatme Sandesh BUY 13,000
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 4 | 2026-06-09 | 4 | view · |
| 8-K | 2026-06-04 | 8-K | view · |
| 4 | 2026-06-02 | 4 | view · |
| 4 | 2026-06-02 | 4 | view · |
| 4 | 2026-06-02 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 10-Q | 2026-05-04 | 10-Q | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| DEF 14A | 2026-04-21 | DEF 14A | view · |
| 4 | 2026-03-24 | 4 | view · |
| 4 | 2026-03-24 | 4 | view · |
| 4 | 2026-03-24 | 4 | view · |
| 4 | 2026-03-24 | 4 | view · |
| 4 | 2026-03-17 | 4 | view · |
| 4 | 2026-03-17 | 4 | view · |
| 4 | 2026-03-17 | 4 | view · |
| 4 | 2026-03-17 | 4 | view · |
| 8-K | 2026-03-16 | 8-K | view · |
| 4 | 2026-03-12 | 4 | view · |
| 4 | 2026-03-12 | 4 | view · |
| 8-K | 2026-03-11 | 8-K | view · |
| 4 | 2026-02-20 | 4 | view · |
| 4 | 2026-02-20 | 4 | view · |
| 10-K | 2026-02-12 | 10-K | view · |
| 8-K | 2026-02-12 | 8-K | view · |
| 4 | 2026-01-27 | 4 | view · |
| 4 | 2026-01-26 | 4 | view · |
| 4 | 2026-01-22 | 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-08 | 4 | view · |
| 4 | 2025-12-23 | 4 | view · |
| 4 | 2025-12-22 | 4 | view · |
| 10-Q | 2025-11-10 | 10-Q | view · |
| 8-K | 2025-11-10 | 8-K | view · |
| 4 | 2025-10-20 | 4 | view · |
| 4 | 2025-10-15 | 4 | view · |
| 4 | 2025-10-15 | 4 | view · |
| 8-K | 2025-10-15 | 8-K | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-09-19 | 4 | view · |
| 4 | 2025-08-19 | 4 | view · |
| 4 | 2025-08-08 | 4 | view · |
| 10-Q | 2025-08-04 | 10-Q | view · |
| 8-K | 2025-08-04 | 8-K | view · |
| 4 | 2025-07-17 | 4 | view · |
| 8-K | 2025-06-26 | 8-K | view · |
| 8-K | 2025-06-09 | 8-K | view · |
| 4 | 2025-06-06 | 4 | view · |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19…
Options picks · CRSP
ITM + OTM ideas from the latest scanLoading…
Congress trades · CRSP
STOCK Act disclosuresLoading…
SEC filings & insiders · CRSP
EDGAR · liveLoading…
Holders · CRSP
Institutions & insider activityLoading…